CytomX Therapeutics, Inc.CTMX
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · United States · cytomx.com
South San Francisco biotechnology company developing masked, conditionally-activated Probody therapeutics, primarily in oncology. Its pipeline includes antibody-drug conjugates designed to localize activity to the tumour microenvironment.
Key ratios
EPS growth
47.5%TTM
FCF / Sales
-450.6%TTM
2025
-99.5%2024
-62.7%2023
-56.2%
Net margin
-166.4%TTM
2025
-22.8%2024
23.1%2023
-0.6%
ROA
-19.6%TTM
2025
-9.0%2024
9.7%2023
-1.8%
ROE
-37.8%TTM
2025
-35.3%
Revenue growth
-87.0%TTM
2025
-44.8%2024
36.5%2023
90.4%
Recent news
CytomX Therapeutics to Present at Upcoming September Investor Conferences
CytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug masetecan ("Varseta-M") for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC)
Track CTMX in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer